S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
How O.J. Simpson burned the Ford Bronco into America's collective memory
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
How O.J. Simpson burned the Ford Bronco into America's collective memory
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
How O.J. Simpson burned the Ford Bronco into America's collective memory
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
How O.J. Simpson burned the Ford Bronco into America's collective memory
NASDAQ:GMAB

Genmab A/S (GMAB) Stock Price, News & Analysis

$29.26
-0.48 (-1.61%)
(As of 04/12/2024 ET)
Today's Range
$29.15
$29.79
50-Day Range
$26.43
$31.68
52-Week Range
$26.32
$42.99
Volume
413,219 shs
Average Volume
390,206 shs
Market Capitalization
$19.33 billion
P/E Ratio
30.48
Dividend Yield
N/A
Price Target
$48.50

Genmab A/S MarketRank™ Stock Analysis

Analyst Rating
Hold
2.38 Rating Score
Upside/​Downside
65.8% Upside
$48.50 Price Target
Short Interest
Healthy
0.37% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.16mentions of Genmab A/S in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
35.85%
From $1.06 to $1.44 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.61 out of 5 stars

Medical Sector

268th out of 923 stocks

Pharmaceutical Preparations Industry

117th out of 430 stocks

GMAB stock logo

About Genmab A/S Stock (NASDAQ:GMAB)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

GMAB Stock Price History

GMAB Stock News Headlines

Options trading has suddenly become more reliable.
When it hits at a stunning 96% win rate... Options trading has suddenly become more reliable.
Genmab A/S (NASDAQ:GMAB) Given "Buy" Rating at HC Wainwright
Options trading has suddenly become more reliable.
When it hits at a stunning 96% win rate... Options trading has suddenly become more reliable.
Transactions in Connection with Share Buy-back Program
Genmab A/S ADR
The 10 best dressed from the 2024 NAACP Image Awards
Completion of share buy-back program
GMAB Apr 2024 30.000 put
Genmab To Repurchase Up To DKK 3.5 Bln Of Shares
Genmab Announces Initiation of Share Buy-Back Program
See More Headlines
Receive GMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/14/2024
Today
4/13/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GMAB
Fax
N/A
Employees
2,204
Year Founded
1999

Price Target and Rating

Average Stock Price Target
$48.50
High Stock Price Target
$50.00
Low Stock Price Target
$46.00
Potential Upside/Downside
+65.8%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
13 Analysts

Profitability

Net Income
$631.91 million
Pretax Margin
34.22%

Debt

Sales & Book Value

Annual Sales
$2.39 billion
Cash Flow
$1.22 per share
Book Value
$6.95 per share

Miscellaneous

Free Float
650,570,000
Market Cap
$19.33 billion
Optionable
Optionable
Beta
0.99

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Dr. Jan G.J. van de Winkel Ph.D. (Age 63)
    Co-Founder, President & CEO
    Comp: $2.9M
  • Mr. Anthony Pagano (Age 46)
    Executive VP & CFO
    Comp: $1.03M
  • Ms. Birgitte Stephensen M.Sc. (Age 63)
    Executive VP & Chief Legal Officer
    Comp: $638.88k
  • Dr. Martine J. van Vugt Ph.D. (Age 53)
    Executive VP & Chief Strategy Officer
    Comp: $696.97k
  • Mr. Martin Schultz (Age 48)
    Senior Director of Clinical Operations & Non-Independent Director
    Comp: $116.16k
  • Dr. Tahamtan Ahmadi (Age 51)
    Executive VP, Chief Medical Officer & Head of Experimental Medicines
    Comp: $1.12M
  • Dr. Mijke Zachariasse Ph.D. (Age 50)
    Senior Director, Head of Antibody Research Materials & Non-Independent Director
    Comp: $159.72k
  • Mr. Takahiro Hamatani (Age 49)
    Senior Director of Finance Japan & Non-Independent Director
    Comp: $116.16k
  • Mr. Anthony Mancini (Age 53)
    Executive VP & COO
    Comp: $1.1M
  • Mr. Andrew Carlsen
    Senior Director, VP & Head of Investor Relations

Should I Buy Genmab A/S Stock? GMAB Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Genmab A/S:

  • Genmab A/S develops innovative antibody therapeutics for the treatment of cancer and other diseases, showing potential for significant growth in the pharmaceutical industry.
  • The company has a diverse product portfolio including DARZALEX, teprotumumab, and Amivantamab, targeting various types of cancer, which could lead to increased revenue streams.
  • Recent upgrades in ratings from neutral to buy by reputable financial institutions like UBS Group and BMO Capital Markets indicate positive market sentiment towards Genmab A/S, potentially driving stock price growth.
  • Collaborations with established companies like Seagen Inc., argenx, and AbbVie demonstrate strong partnerships that could enhance research and development capabilities, leading to potential breakthrough therapies.
  • Genmab A/S has a robust pipeline of pre-clinical programs and ongoing clinical trials, suggesting a promising future for the company's product development and market expansion.

Cons

Investors should be bearish about investing in Genmab A/S for these reasons:

  • Despite recent positive ratings upgrades, some analysts have issued sell ratings on Genmab A/S, indicating potential risks or uncertainties in the company's performance or market conditions.
  • The pharmaceutical industry is highly competitive and subject to regulatory challenges, which could impact the success and market acceptance of Genmab A/S' products.
  • Market volatility and economic uncertainties may affect the stock price of Genmab A/S, leading to potential fluctuations in investment returns.
  • Dependency on a few key products like DARZALEX for a significant portion of revenue poses a risk in case of unexpected market changes or competition from alternative therapies.
  • Investors should carefully monitor the progress of Genmab A/S' clinical trials and product launches to assess the company's ability to deliver on its pipeline and revenue projections.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 10, 2024. Please send any questions or comments about these Genmab A/S pros and cons to contact@marketbeat.com.

GMAB Stock Analysis - Frequently Asked Questions

Should I buy or sell Genmab A/S stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last twelve months. There are currently 3 sell ratings, 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GMAB, but not buy additional shares or sell existing shares.
View GMAB analyst ratings
or view top-rated stocks.

What is Genmab A/S's stock price target for 2024?

13 analysts have issued 1-year target prices for Genmab A/S's shares. Their GMAB share price targets range from $46.00 to $50.00. On average, they expect the company's share price to reach $48.50 in the next twelve months. This suggests a possible upside of 65.8% from the stock's current price.
View analysts price targets for GMAB
or view top-rated stocks among Wall Street analysts.

How have GMAB shares performed in 2024?

Genmab A/S's stock was trading at $31.84 on January 1st, 2024. Since then, GMAB shares have decreased by 8.1% and is now trading at $29.26.
View the best growth stocks for 2024 here
.

Are investors shorting Genmab A/S?

Genmab A/S saw a increase in short interest in March. As of March 31st, there was short interest totaling 2,400,000 shares, an increase of 17.1% from the March 15th total of 2,050,000 shares. Based on an average trading volume of 626,600 shares, the short-interest ratio is presently 3.8 days. Approximately 0.4% of the company's stock are short sold.
View Genmab A/S's Short Interest
.

When is Genmab A/S's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our GMAB earnings forecast
.

How were Genmab A/S's earnings last quarter?

Genmab A/S (NASDAQ:GMAB) announced its quarterly earnings data on Wednesday, February, 14th. The company reported $0.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.02. The firm earned $675.29 million during the quarter, compared to analyst estimates of $678.14 million. Genmab A/S had a net margin of 26.50% and a trailing twelve-month return on equity of 18.06%.

What guidance has Genmab A/S issued on next quarter's earnings?

Genmab A/S updated its FY 2024 earnings guidance on Wednesday, February, 14th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.7 billion-$3.0 billion, compared to the consensus revenue estimate of $2.8 billion.

What other stocks do shareholders of Genmab A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genmab A/S investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), CVS Health (CVS), Home Depot (HD), Intel (INTC), Pfizer (PFE), PayPal (PYPL), Verizon Communications (VZ) and Cisco Systems (CSCO).

When did Genmab A/S IPO?

Genmab A/S (GMAB) raised $503 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 27,800,000 shares at $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies served as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers.

Who are Genmab A/S's major shareholders?

Genmab A/S's stock is owned by many different institutional and retail investors. Top institutional shareholders include Marotta Asset Management (0.00%), Park Avenue Securities LLC (0.00%) and GAMMA Investing LLC (0.00%).

How do I buy shares of Genmab A/S?

Shares of GMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GMAB) was last updated on 4/13/2024 by MarketBeat.com Staff

From Our Partners